A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).

Geller, James I; Fox, Elizabeth; Turpin, Brian K; Goldstein, Stuart L; Liu, Xiaowei; Minard, Charles G; Kudgus, Rachel A; Reid, Joel M; Berg, Stacey L; Weigel, Brenda J

Geller, James I; Fox, Elizabeth; Turpin, Brian K; Goldstein, Stuart L; Liu, Xiaowei; Minard, Charles G; Kudgus, Rachel A; Reid, Joel M; Berg, Stacey L; Weigel, Brenda J.

Afiliación

Geller JI; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
Fox E; Developmental Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Turpin BK; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
Goldstein SL; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
Liu X; Children's Oncology Group, Monrovia, California.
Minard CG; Dan L, Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas.
Kudgus RA; Department of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Reid JM; Department of Oncology Research, Mayo Clinic, Rochester, Minnesota.
Berg SL; Dan L, Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas.
Weigel BJ; Department of Pediatrics, Masonic Children's Hospital, University of Minnesota Medical Center, Minneapolis, Minnesota.

Cancer ; 124(23): 4548-4555, 2018 12 01.

Article en En | MEDLINE | ID: mdl-30394521

Asunto(s)

Axitinib/administración & dosificación; Recurrencia Local de Neoplasia/tratamiento farmacológico; Neoplasias/tratamiento farmacológico; Inhibidores de Proteínas Quinasas/administración & dosificación; Administración Oral; Adolescente; Axitinib/efectos adversos; Axitinib/farmacocinética; Niño; Esquema de Medicación; Femenino; Humanos; Masculino; Dosis Máxima Tolerada; Proyectos Piloto; Inhibidores de Proteínas Quinasas/efectos adversos; Inhibidores de Proteínas Quinasas/farmacocinética; Análisis de Supervivencia; Resultado del Tratamiento

Palabras clave

Inlyta; axitinib; pediatric solid tumor; phase 1; vascular endothelial growth factor receptor (VEGFR)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Axitinib / Recurrencia Local de Neoplasia / Neoplasias Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google